OPRM1 and hepatocellular carcinoma: Further studies are required to confirm MOR usefulness as a therapeutic target in HCC; however, preliminary data seem to be encouraging for development of therapeutic MOR inhibitors aiming to inactivate downstream EMT molecular signatures.